A detailed history of China Universal Asset Management Co., Ltd. transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 5,526 shares of KRYS stock, worth $1.09 Million. This represents 0.11% of its overall portfolio holdings.

Number of Shares
5,526
Previous 3,354 64.76%
Holding current value
$1.09 Million
Previous $615,000 63.25%
% of portfolio
0.11%
Previous 0.09%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$174.7 - $213.66 $379,448 - $464,069
2,172 Added 64.76%
5,526 $1 Million
Q2 2024

Jul 19, 2024

SELL
$153.12 - $183.64 $322,930 - $387,296
-2,109 Reduced 38.61%
3,354 $615,000
Q1 2024

Apr 29, 2024

BUY
$108.01 - $179.35 $238,054 - $395,287
2,204 Added 67.63%
5,463 $972,000
Q4 2023

May 21, 2024

SELL
$96.0 - $128.29 $211,584 - $282,751
-2,204 Reduced 40.34%
3,259 $404,000
Q4 2023

Jan 23, 2024

BUY
$96.0 - $128.29 $243,936 - $325,984
2,541 Added 353.9%
3,259 $404,000
Q3 2023

May 21, 2024

BUY
$108.51 - $130.22 $41,125 - $49,353
379 Added 111.8%
718 $83,000
Q3 2023

Oct 30, 2023

BUY
$108.51 - $130.22 $41,125 - $49,353
379 Added 111.8%
718 $83,000
Q2 2023

May 21, 2024

SELL
$78.48 - $130.32 $784 - $1,303
-10 Reduced 2.87%
339 $39,000
Q2 2023

Jul 27, 2023

SELL
$78.48 - $130.32 $784 - $1,303
-10 Reduced 2.87%
339 $40,000
Q1 2023

May 21, 2024

BUY
$72.39 - $84.27 $6,297 - $7,331
87 Added 33.21%
349 $27,000
Q1 2023

Apr 27, 2023

BUY
$72.39 - $84.27 $6,297 - $7,331
87 Added 33.21%
349 $28,000
Q4 2022

May 21, 2024

SELL
$63.14 - $79.9 $328,391 - $415,559
-5,201 Reduced 95.2%
262 $20,000
Q4 2022

Jan 31, 2023

BUY
$63.14 - $79.9 $1,389 - $1,757
22 Added 9.17%
262 $21,000
Q3 2022

Oct 21, 2022

BUY
$64.85 - $82.4 $15,563 - $19,776
240 New
240 $17,000

Others Institutions Holding KRYS

About Krystal Biotech, Inc.


  • Ticker KRYS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,664,300
  • Market Cap $5.04B
  • Description
  • Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...
More about KRYS
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.